BioArctic and Eisai sign research evaluation agreement regarding BAN2802

Contributed by: PR Newswire

Tags

Bioarctic

More Like This

BioArctic and Novartis sign an option, collaboration and license agreement using BrainTransporter™ for an upfront payment of USD 30 million plus additional potential milestones and royalties

The drug discovery research for lecanemab awarded the 9th Bioindustry Award by the Japan Bioindustry Association

Update relating to LEQEMBI® from Eisai's investor presentation of their quarterly report published today

BioArctic's partner Eisai presents updated sales simulation for Leqembi® at its annual press conference

BioArctic: Latest data on lecanemab to be presented at the 2024 AD/PD™ congress

Lecanemab winner in two categories at The Scrip Awards 2023

BioArctic: New data on lecanemab presented at the 2024 AD/PD™ congress

Long-term treatment data for lecanemab to be presented at AAIC 2024